[{"indications": "Indications\u00a0prophylaxis of asthma, see notes above and %s\n(From Management of chronic asthma: British National Formulary)\nManagement of chronic asthma", "name": "ZAFIRLUKAST", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.3 Cromoglicate\r\nand related therapy, leukotriene receptor antagonists, and phosphodiesterase\r\ntype-4 inhibitors", "3.3.2 Leukotriene receptor antagonists"], "cautions": "Cautions\u00a0elderly; interactions: Appendix 1 (leukotriene receptor antagonists)Hepatic disorders\u00a0Patients or their\r\ncarers should be told how to recognise development of liver disorder\r\nand advised to seek medical attention if symptoms or signs such as\r\npersistent nausea, vomiting, malaise, or jaundice develop", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances, respiratory infections,\r\nheadache, insomnia, malaise; rarely bleeding disorders,\r\nhypersensitivity reactions including angioedema and skin reactions,\r\narthralgia, myalgia, hepatitis, hyperbilirubinaemia, thrombocytopenia; very rarely Churg-Strauss syndrome (\n(From 3.3.2 Leukotriene receptor antagonists: British National Formulary)\nChurg-Strauss syndrome has occurred very rarely in association with the use of leukotriene receptor antagonists; in many of the reported cases the reaction followed the reduction or withdrawal of oral corticosteroid therapy. Prescribers should be alert to the development of eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, or peripheral neuropathy.), agranulocytosis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/72980.htm", "doses": ["adult and child over 12 years, 20\u00a0mg twice daily"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk; see also notes above"}]